CO4340618A1 - PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE - Google Patents

PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE

Info

Publication number
CO4340618A1
CO4340618A1 CO94056072A CO94056072A CO4340618A1 CO 4340618 A1 CO4340618 A1 CO 4340618A1 CO 94056072 A CO94056072 A CO 94056072A CO 94056072 A CO94056072 A CO 94056072A CO 4340618 A1 CO4340618 A1 CO 4340618A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
controlled release
around
weight
substance
Prior art date
Application number
CO94056072A
Other languages
Spanish (es)
Inventor
Martin Howard Infeld
A Waseen Malick
Wantanee Phuapradit
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4340618A1 publication Critical patent/CO4340618A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

UNA COMPOSICION FARMACEUTICA EROSIONABLE, CONFI- GURADA Y COMPRIMIDA PARA CONSTITUIR UNA FORMA DE DOSIFICACION UNITARIA SOLIDA, QUE PROPORCIONA UNA LIBERACION CONTROLADA DE ORDEN CERO DE UNA SUSTAN- CIA TERAPEUTICAMENTE ACTIVA, COMPRENDIENDO LA COMPOSICION EROSIONABLE ENTRE ALREDEDOR DEL 5% A 60% PESO/PESO DE UNA SUSTANCIA TERAPEUTICAMENTE ACTIVA QUE TIENE UNA SOLUBILIDAD NO SUPERIOR A 80 mg/ml EN AGUA A 25 GRADOS CENTIGRADOS Y POR LO MENOS ALREDEDOR DE 5% HASTA ALREDEDOR DE 50% PESO/PESO DE UNA HIDROXIPROPIL METILCELULOSA DE BAJA VISCOSIDAD Y EL RESTO DE LA COMPOSICION ERO- SIONABLE CONSTITUIDO POR VEHICULOS INERTES. .AN EROSIONABLE PHARMACEUTICAL COMPOSITION, CONFIGURED AND COMPRESSED TO CONSTITUTE A SOLID UNIT DOSAGE FORM, WHICH PROVIDES A ZERO-ORDERLY CONTROLLED RELEASE OF A SUBSTANCE SUBSTANTIALLY ACTIVE BY 5% ALONG 5% OF A THERAPEUTICALLY ACTIVE SUBSTANCE THAT HAS A SOLUBILITY OF NO MORE THAN 80 mg / ml IN WATER AT 25 DEGREES DEGREE AND AT LEAST AROUND 5% UP TO AROUND 50% WEIGHT / WEIGHT OF A LOW VISCOS HYDROXYPROPIL AND EROUSABLE COMPOSITION CONSTITUTED BY INERT VEHICLES. .

CO94056072A 1993-12-13 1994-12-12 PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE CO4340618A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/166,123 US5393765A (en) 1993-12-13 1993-12-13 Pharmaceutical compositions with constant erosion volume for zero order controlled release

Publications (1)

Publication Number Publication Date
CO4340618A1 true CO4340618A1 (en) 1996-07-30

Family

ID=22601916

Family Applications (1)

Application Number Title Priority Date Filing Date
CO94056072A CO4340618A1 (en) 1993-12-13 1994-12-12 PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE

Country Status (22)

Country Link
US (1) US5393765A (en)
EP (1) EP0662322B1 (en)
JP (1) JP2966745B2 (en)
KR (1) KR950016783A (en)
CN (1) CN1110135A (en)
AT (1) ATE214919T1 (en)
AU (1) AU688807B2 (en)
BR (1) BR9404953A (en)
CA (1) CA2136118A1 (en)
CO (1) CO4340618A1 (en)
CZ (1) CZ287718B6 (en)
DE (1) DE69430237T2 (en)
ES (1) ES2171431T3 (en)
HU (1) HU219227B (en)
IL (1) IL111920A (en)
NO (1) NO944803L (en)
NZ (1) NZ270058A (en)
PL (1) PL306245A1 (en)
RU (1) RU2174832C2 (en)
TW (1) TW438597B (en)
UA (1) UA41887C2 (en)
ZA (1) ZA949711B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5869079A (en) † 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6503528B1 (en) * 1999-11-19 2003-01-07 Abbott Laboratories Polymeric compositions and a method of making the same
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005526079A (en) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド NE and 5-HT reuptake inhibitors for treating visceral pain syndrome
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MXPA05008033A (en) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Multiparticulate compositions of milnacipran for oral administration.
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US7476403B2 (en) * 2003-06-16 2009-01-13 Andrx Pharmaceuticals, Llc Oral extended-release composition
JP2006528185A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
JP2006528189A (en) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic products, their use and formulation
EP1648407A4 (en) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
US8758820B2 (en) * 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
EP1653924A4 (en) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
KR100635301B1 (en) * 2004-09-15 2006-10-17 지엘팜텍 주식회사 A sustained-release tablet containing doxazosin mesylate
KR100920856B1 (en) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 Extended-release preparation containing selective serotonin reuptake inhibitor and process for the preparation thereof
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AU2008312321A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
EP2389163B1 (en) 2009-01-23 2021-09-01 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. Controlled release pharmaceutical or food formulation and process for its preparation
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
FR2535202B1 (en) * 1982-11-03 1985-08-09 Fabre Sa Pierre CONTROLLED RELEASE THEOPHYLLIN TABLETS AND PROCESS FOR THEIR MANUFACTURE
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
FR2591105B1 (en) * 1985-12-11 1989-03-24 Moet Hennessy Rech PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID.
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
SE9003904D0 (en) * 1990-12-07 1990-12-07 Astra Ab METHOD FOR THE MANUFACTURE OF A PHARMACEUTICAL DOSAGE FORM
ATE183642T1 (en) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical DELAYED-RELEASE TABLET
DE69301742T2 (en) * 1992-02-17 1996-08-14 Siegfried Ag Pharma Dosage forms with extended release of active ingredient

Also Published As

Publication number Publication date
DE69430237T2 (en) 2002-07-18
AU8023294A (en) 1995-06-22
RU2174832C2 (en) 2001-10-20
TW438597B (en) 2001-06-07
IL111920A0 (en) 1995-03-15
CZ287718B6 (en) 2001-01-17
JPH07196535A (en) 1995-08-01
NO944803L (en) 1995-06-14
KR950016783A (en) 1995-07-20
EP0662322A2 (en) 1995-07-12
CA2136118A1 (en) 1995-06-14
UA41887C2 (en) 2001-10-15
CN1110135A (en) 1995-10-18
EP0662322A3 (en) 1997-01-29
PL306245A1 (en) 1995-06-26
DE69430237D1 (en) 2002-05-02
NZ270058A (en) 1996-07-26
HU219227B (en) 2001-03-28
HUT75456A (en) 1997-05-28
ATE214919T1 (en) 2002-04-15
BR9404953A (en) 1995-08-08
JP2966745B2 (en) 1999-10-25
ES2171431T3 (en) 2002-09-16
AU688807B2 (en) 1998-03-19
HU9403496D0 (en) 1995-02-28
ZA949711B (en) 1995-08-21
NO944803D0 (en) 1994-12-12
RU94043809A (en) 1996-11-10
US5393765A (en) 1995-02-28
IL111920A (en) 1999-08-17
CZ312794A3 (en) 1995-09-13
EP0662322B1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
CO4340618A1 (en) PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE
AR042977A1 (en) PALONOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
ECSP941104A (en) DERIVATIVES OF 2,6 DIAMINOPURINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR059324A2 (en) A solid form of oral dosing
DE69812343D1 (en) SOLID PHARMACEUTICAL FORMULATIONS CONTAINING A PHYSICAL MIXTURE OF SULPHOALKYLETHERCYCLODEXTRIN AND A THERAPEUTIC ACTIVE SUBSTANCE
AR069942A2 (en) PHARMACEUTICAL FORMS OF DOSAGE CONTAINING IBANDRONIC ACID
ES2091441T3 (en) PHARMACEUTICAL COMPOSITION.
CR7938A (en) PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC ERYTHEMATE LUPUS
ES2077530B1 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PRODUCTS TO CURE TUMOR DISEASES.
ES2180738T3 (en) SOLID PREPARATIONS OF ACTIVE PRODUCTS.
AR018732A1 (en) IMINOAZUCARES RENTED TO PREVENT, REDUCE OR REVERT THE RESISTANCE TO MULTIDROGA IN THE CHEMOTHERAPEUTIC AND COMPOSITION PHARMACEUTICAL TREATMENT CONTAINING THEM.
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
AR033688A1 (en) RECONSTITUABLE PARENTERAL COMPOSITION
MX9301700A (en) MUTEINS OF THE HUMAN TUMOR NECROSIS FACTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CO5640149A2 (en) PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF ERYTHEMATE SYSTEM LUPUS
AR006598A1 (en) "ANTI-FUNGOUS COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES AND A PROCEDURE FOR THE PREPARATION"
AR023806A1 (en) USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
ES2178048T3 (en) USE OF RIFAXIMINE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF DIARRHEA BY CRYPTOSPORIDIOSIS.
AR006401A1 (en) PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.
CO4940406A1 (en) QUICK-ACTION PARACETAMOL COMPOSITIONS
IT1263840B (en) ORAL FORMULATIONS OF UBIDECARENONE IN THE FORM OF CAPSULES
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
AR010122A1 (en) RECOVERY PROCEDURE FOR HIGHLY PURIFIED VWF OR HIGHLY PURIFIED FACTOR VIII / VWF COMPLEX
MX9205568A (en) PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE.
BE906034A (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING UBIQUINONE AS ACTIVE INGREDIENT USEFUL IN DIFFERENT THERAPEUTIC APPLICATIONS